nach oben

Inflammation Research

Erschienen in:

01.06.2011 | Original Research Paper

Effects of endogenous substance P expression on degranulation in RBL-2H3 cells

verfasst von: Hua Hu, Ruxin Zhang, Xiaoyun Fang, Min Yu, Shaoqing Yu, Jie Zhang, Hong Wang

Erschienen in: Inflammation Research | Ausgabe 6/2011

Einloggen, um Zugang zu erhalten

Abstract

Objective and design

To determine whether RBL-2H3 cells have endogenous substance P (SP) expression under immunoglobulin E (IgE)-activated and inactivated conditions, and to ascertain the function of endogenous SP in the antigen-induced degranulation of RBL-2H3 cells.

Materials and methods

SP mRNA and protein expression in both inactivated and 2,4-dinitrophenol (DNP)-specific IgE-activated RBL-2H3 cells were assessed by real-time PCR and immunofluorescence, respectively. Following activation with DNP-specific IgE, the degranulation of RBL-2H3 cells in response to DNP–bovine serum albumin (BSA), with and without endogenous SP expression, was assessed by monitoring the release of the granular enzyme β-hexosaminidase.

Results

Endogenous SP mRNA and peptide expression increased in activated RBL-2H3 cells, compared with inactivated RBL-2H3 cells. The small hairpin RNA (shRNA)-mediated knockdown of endogenous SP reduced the degranulation ability of RBL-2H3 cells.

Conclusions

Activated RBL-2H3 cells express endogenous SP which plays a role in antigen-induced degranulation.

Sarin S, Undem B, Sanico A, Togias A. The role of the nervous system in rhinitis. J Allergy Clin Immunol. 2006;118:999–1016.PubMedCrossRef

O’Connor TM, O’Connell J, O’Brien DI, Goode T, Bredin CP, Shanahan F. The role of substance P in inflammatory disease. J Cell Physiol. 2004;201:167–80.PubMedCrossRef

Stoyanova II, Gulubova MV. Mast cells and inflammatory mediators in chronic ulcerative colitis. Acta Histochem. 2002;104:185–92.PubMedCrossRef

O’Dorisio MS, Wood CL, O’Dorisio TM. Vasoactive intestinal peptide and neuropeptide modulation of the immune response. J Immunol. 1985;135:792s–6s.PubMed

Fewtrell CM, Foreman JC, Jordan CC, Oehme P, Renner H, Stewart JM. The effects of substance P on histamine and 5-hydroxytryptamine release in the rat. J Physiol. 1982;330:393–411.PubMed

Nawa H, Kotani H, Nakanishi S. Tissue-specific generation of two preprotachykinin mRNAs from one gene by alternative RNA splicing. Nature. 1984;312:729–34.PubMedCrossRef

Bienenstock J, MacQueen G, Sestini P, Marshall JS, Stead RH, Perdue MH. Mast cell/nerve interactions in vitro and in vivo. Am Rev Respir Dis. 1991;143:S55–8.PubMed

Lau AH, Chow SS, Ng YS. Immunologically induced histamine release from rat peritoneal mast cells is enhanced by low levels of substance P. Eur J Pharmacol. 2001;414:295–303.PubMedCrossRef

Qian BF, Zhou GQ, Hammarstrom ML, Danielsson A. Both substance P and its receptor are expressed in mouse intestinal T lymphocytes. Neuroendocrinology. 2001;73:358–68.PubMedCrossRef

10.

Ho WZ, Lai JP, Zhu XH, Uvaydova M, Douglas SD. Human monocytes and macrophages express substance P and neurokinin-1 receptor. J Immunol. 1997;159:5654–60.PubMed

11.

Killingsworth CR, Shore SA, Alessandrini F, Dey RD, Paulauskis JD. Rat alveolar macrophages express preprotachykinin gene-I mRNA-encoding tachykinins. Am J Physiol. 1997;273:L1073–81.PubMed

12.

Weinstock JV, Blum AM. Release of substance P by granuloma eosinophils in response to secretagogues in murine schistosomiasis mansoni. Cell Immunol. 1990;125:380–5.PubMedCrossRef

13.

Metwali A, Blum AM, Ferraris L, Klein JS, Fiocchi C, Weinstock JV. Eosinophils within the healthy or inflamed human intestine produce substance P and vasoactive intestinal peptide. J Neuroimmunol. 1994;52:69–78.PubMedCrossRef

14.

Gilfillan AM, Rivera J. The tyrosine kinase network regulating mast cell activation. Immunol Rev. 2009;228:149–69.PubMedCrossRef

15.

Harmar AJ, Hyde V, Chapman K. Identification and cDNA sequence of delta-preprotachykinin, a fourth splicing variant of the rat substance P precursor. FEBS Lett. 1990;275:22–4.PubMedCrossRef

16.

Ali H, Richardson RM, Tomhave ED, DuBose RA, Haribabu B, Snyderman R. Regulation of stably transfected platelet activating factor receptor in RBL-2H3 cells. Role of multiple G proteins and receptor phosphorylation. J Biol Chem. 1994;269:24557–63.PubMed

17.

Fowler CJ, Sandberg M, Tiger G. Effects of water-soluble cigarette smoke extracts upon the release of beta-hexosaminidase from RBL-2H3 basophilic leukaemia cells in response to substance P, compound 48/80, concanavalin A and antigen stimulation. Inflamm Res. 2003;52:461–9.PubMedCrossRef

18.

Frieri M. Neuroimmunology and inflammation: implications for therapy of allergic and autoimmune diseases. Ann Allergy Asthma Immunol. 2003;90:34–40.PubMedCrossRef

19.

Bost KL, Breeding SA, Pascual DW. Modulation of the mRNAs encoding substance P and its receptor in rat macrophages by LPS. Reg Immunol. 1992;4:105–12.PubMed

20.

Shanahan F, Denburg JA, Fox J, Bienenstock J, Befus D. Mast cell heterogeneity: effects of neuroenteric peptides on histamine release. J Immunol. 1985;135:1331–7.PubMed

21.

van der Kleij HP, Ma D, Redegeld FA, Kraneveld AD, Nijkamp FP, Bienenstock J. Functional expression of neurokinin 1 receptors on mast cells induced by IL-4 and stem cell factor. J Immunol. 2003;171:2074–9.PubMed

22.

Leon A, Buriani A, Dal Toso R, Fabris M, Romanello S, Aloe L, et al. Mast cells synthesize, store, and release nerve growth factor. Proc Natl Acad Sci USA. 1994;91:3739–43.PubMedCrossRef

23.

Swieter M, Midura RJ, Nishikata H, Oliver C, Berenstein EH, Mergenhagen SE, et al. Mouse 3T3 fibroblasts induce rat basophilic leukemia (RBL-2H3) cells to acquire responsiveness to compound 48/80. J Immunol. 1993;150:617–24.PubMed

24.

Liao BC, Hou RC, Wang JS, Jeng KC. Enhancement of the release of inflammatory mediators by substance P in rat basophilic leukemia RBL-2H3 cells. J Biomed Sci. 2006;13:613–9.PubMedCrossRef

25.

Okada T, Hirayama Y, Kishi S, Miyayasu K, Hiroi J, Fujii T. Functional neurokinin NK-1 receptor expression in rat peritoneal mast cells. Inflamm Res. 1999;48:274–9.PubMedCrossRef

26.

Hua XY, Back SM, Tam EK. Substance P enhances electrical field stimulation-induced mast cell degranulation in rat trachea. Am J Physiol. 1996;270:L985–91.PubMed

27.

Columbo M, Horowitz EM, Kagey-Sobotka A, Lichtenstein LM. Substance P activates the release of histamine from human skin mast cells through a pertussis toxin-sensitive and protein kinase C-dependent mechanism. Clin Immunol Immunopathol. 1996;81:68–73.PubMedCrossRef

28.

Lorenz D, Wiesner B, Zipper J, Winkler A, Krause E, Beyermann M, et al. Mechanism of peptide-induced mast cell degranulation. Translocation and patch-clamp studies. J Gen Physiol. 1998;112:577–91.PubMedCrossRef

29.

Ohshiro H, Suzuki R, Furuno T, Nakanishi M. Atomic force microscopy to study direct neurite-mast cell (RBL) communication in vitro. Immunol Lett. 2000;74:211–4.PubMedCrossRef

30.

Hanf G, Schierhorn K, Brunnee T, Noga O, Verges D, Kunkel G. Substance P induced histamine release from nasal mucosa of subjects with and without allergic rhinitis. Inflamm Res. 2000;49:520–3.PubMedCrossRef

31.

Chapman RW, Hey JA, McLeod R, Minnicozzi M, Rizzo C. Tachykinins in the lungs. Drug News Perspect. 1998;11:480–9.PubMed

Titel: Effects of endogenous substance P expression on degranulation in RBL-2H3 cells
verfasst von: Hua Hu
Ruxin Zhang
Xiaoyun Fang
Min Yu
Shaoqing Yu
Jie Zhang
Hong Wang
Publikationsdatum: 01.06.2011
Verlag: SP Birkhäuser Verlag Basel
Erschienen in: Inflammation Research / Ausgabe 6/2011
Print ISSN: 1023-3830
Elektronische ISSN: 1420-908X
DOI: https://doi.org/10.1007/s00011-010-0301-6

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Bei Herzinsuffizienz muss „Eisenmangel“ neu definiert werden!

16.05.2024 Herzinsuffizienz Nachrichten

Bei chronischer Herzinsuffizienz macht es einem internationalen Expertenteam zufolge wenig Sinn, die Diagnose „Eisenmangel“ am Serumferritin festzumachen. Das Team schlägt vor, sich lieber an die Transferrinsättigung zu halten.

Herzinfarkt mit 85 – trotzdem noch intensive Lipidsenkung?

16.05.2024 Hypercholesterinämie Nachrichten

Profitieren nach einem akuten Myokardinfarkt auch Betroffene über 80 Jahre noch von einer intensiven Lipidsenkung zur Sekundärprävention? Um diese Frage zu beantworten, wurden jetzt Registerdaten aus Frankreich ausgewertet.

ADHS-Medikation erhöht das kardiovaskuläre Risiko

16.05.2024 Herzinsuffizienz Nachrichten

Erwachsene, die Medikamente gegen das Aufmerksamkeitsdefizit-Hyperaktivitätssyndrom einnehmen, laufen offenbar erhöhte Gefahr, an Herzschwäche zu erkranken oder einen Schlaganfall zu erleiden. Es scheint eine Dosis-Wirkungs-Beziehung zu bestehen.

Erstmanifestation eines Diabetes-Typ-1 bei Kindern: Ein Notfall!

16.05.2024 DDG-Jahrestagung 2024 Kongressbericht

Manifestiert sich ein Typ-1-Diabetes bei Kindern, ist das ein Notfall – ebenso wie eine diabetische Ketoazidose. Die Grundsäulen der Therapie bestehen aus Rehydratation, Insulin und Kaliumgabe. Insulin ist das Medikament der Wahl zur Behandlung der Ketoazidose.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Objective and design

Materials and methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2011

Atherosclerosis aggravates ischemia/reperfusion injury in the gut and remote damage in the liver and the lung

Urinary trypsin inhibitor attenuates lipopolysaccharide-induced acute lung injury by blocking the activation of p38 mitogen-activated protein kinase

Erratum to: Human skin penetration of a copper tripeptide in vitro as a function of skin layer

Inflammatory pattern recognition receptors and their ligands: factors contributing to the pathogenesis of preeclampsia

Anti-inflammatory effects of ivermectin in mouse model of allergic asthma